Overview

Intravenous Thrombolysis With rhTNK-tPA for Acute Non-large Vessel Occlusion in Extended Time Window

Status:
Not yet recruiting

Trial end date:
2024-12-30

Target enrollment:

Participant gender:

Summary

This study is designed to evaluate the efficacy of IV rhTNK-tPA between 4.5 to 24 hours from symptom onset in patients presenting with a non-large vessel occlusion ischemic stroke.

Phase:

Phase 4

Details

Lead Sponsor:

Xuanwu Hospital, Beijing

Collaborator:

Guangzhou Recomgen Biotech Co., Ltd.

Treatments:

Clopidogrel
Platelet Aggregation Inhibitors